CLINICAL NEWS |
|||
interruptions in 16 people ( 26 %).
Except for IRRs , the safety profile of the brentuximab vedotin and nivolumab were similar to those observed with each agent administered individually .
“ Our results are promising in the context of other salvage therapy studies in relapsed / refractory HL , a setting in which no randomized studies have been performed to define a single standard of care regimen prior to AHCT ,” the authors concluded .
|
However , they noted that the study is limited by its short-term follow-up and lack of a comparator arm . “ Long-term follow-up of the durability of disease control will be critical in assessing the full therapeutic impact of [ this combination ],” the researchers added . Also , the study population only included patients who were naïve to prior brentuximab vedotin and nivolumab , and outcomes may not be generalizable to other patients with |
relapsed / refractory HL .
An ongoing trial is evaluating brentuximab vedotin plus nivolumab in patients with relapsed / refractory HL who are ineligible for AHCT or after AHCT failure .
Seattle Genetics and Bristol-Myers Squibb supported the study .
The corresponding authors report financial support from Seattle Genetics , Bristol-Myers Squibb , MedImmune , Merck , Immune Design , Genentech , Pharmacyclics ,
|
Janssen , Affimed , ImaginAb , KITE , Forty Seven , Celgene , AstraZeneca , Millennium , Pfizer , and Novartis . Some of the authors are employees of and have equity ownership in Seattle Genetics , which provided editorial support for the original manuscript .
REFERENCE
Herrera AF , Moskowitz AJ , Bartlett NL , et al . Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma . Blood . 2017 November 30 . [ Epub ahead of print ]
|
1
0 6 12 18 24 30 36 42 48
|
Time , h
Data are geometric means , based on chromogenic assay .
Print-only content
|
Advate ®
4.5 IU / dL
|
S : 9.75 ” |
T : 10 ” |
||
Compared to Advate ® , KOVALTRY ® demonstrated 2 : |